NCT00002172
Completed
Not Applicable
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml
The Immune Response Corporation1 site in 1 countryAugust 31, 2001
ConditionsHIV Infections
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- The Immune Response Corporation
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.HIV InfectionsNCT00002173The Immune Response Corporation
Completed
Phase 4
Fosamprenavir Expanded AccessInfection, Human Immunodeficiency VirusNCT00240552ViiV Healthcare85
Active, not recruiting
Not Applicable
GW433908 Expanded Access Program for HIV infected subjects non responding or intolerant to the previous antiretroviral treatmentsHIV infectionMedDRA version: 6.1Level: PTClassification code 10020161EUCTR2004-000336-81-ITGLAXO SMITHKLINE1,500
No Longer Available
Not Applicable
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
Available
Not Applicable
Expanded Access to TriheptanoinLong Chain Fatty Acid Oxidation DisordersNCT03773770Ultragenyx Pharmaceutical Inc